• 1986:
    Founded by Wei-Cheng WANG, the current president of EB Pharma
  • 1990:
    Acquired the distribution right of Zatiden for Northern Taiwan from Sandoz
  • 1993:
    Acquired the distribution right of Voltaren for Northern Taiwan from Ciba-Geigy
  • 1996:
    With the merger of Sandoz and Ciba-Geigy into Novartis, EB Pharma became the largest distributor of Novartis in Taiwan, marketing more products such as Parlodel, Clozaril, Etumine, and Hydergine
  • 2003:
    Started to develop own branded generic products in Taiwan
  • 2004:
    First own branded generic Meto 250mg (Metformin) launched
  • 2005:
    Suride 200mg (Sulpiride) launched
  • 2007:
    Epram 10mg (Escitalopram) and Pane 40mg IV (Pantoprazole) launched
  • 2009:
    Fute 0.5/5mg (Flupentixol) launched as EB's first specialty generic products
  • 2011:
    Epine 25/200/300mg (Quetiapine) launched
  • 2012:
    Annual sales reached NT$ 150 million; Epram 10mg became the best selling generic version of Escitalopram in Taiwan
  • 2014:
    Ritalin (partial channels), Ritalin LA (partial channels), Cibacen, Nitroderm TTS were added to our Novartis portfolio
  • 2015:
    Annual sales reached NT$ 200 million
  • 2016:
    Annual sales reached NT$ 300 million,Trileptal, Tegretol, Exelon (partial channels), Comtan (partial channels)、Stalevo (partial channels) were added to our Novartis portfolio
  • 2017:
    Annual sales reached NT$ 350 million
  • 2018:
    Ritalin IR and Ritalin LA marketing right of all remaining channels were added to our Novartis portfolio